Renaissance Technologies (RenTech)'s DMAC Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 52,523 shares of DiaMedica Therapeutics Inc. (DMAC) worth $355,581, representing 0.00% of the portfolio. First purchased in 2020-Q1, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in DMAC, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2020, adding 78,851 shares. Largest reduction occurred in Q3 2021, reducing 94,100 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s DiaMedica Therapeutics (DMAC) Holding Value Over Time
Track share changes against reported price movement
Quarterly DiaMedica Therapeutics (DMAC) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +52,523 | New Buy | 52,523 | $6.77 |
| Q2 2023 | -64,508 | Sold Out | 0 | $0.00 |
| Q1 2023 | +30,889 | Add 91.88% | 64,508 | $0.00 |
| Q4 2022 | +33,619 | New Buy | 33,619 | $0.00 |
| Q3 2021 | -94,100 | Sold Out | 0 | $0.00 |
| Q2 2021 | -59,000 | Reduce 38.54% | 94,100 | $4.45 |
| Q1 2021 | +39,700 | Add 35.01% | 153,100 | $9.15 |
| Q4 2020 | +17,400 | Add 18.12% | 113,400 | $10.14 |
| Q3 2020 | -8,700 | Reduce 8.31% | 96,000 | $4.24 |
| Q2 2020 | +78,851 | Add 305.04% | 104,700 | $6.93 |
| Q1 2020 | +25,849 | New Buy | 25,849 | $2.79 |
Renaissance Technologies (RenTech)'s DiaMedica Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased DiaMedica Therapeutics Inc. (DMAC) in Q1 2020, acquiring 25,849 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held DiaMedica Therapeutics Inc. (DMAC) for 11 quarters since Q1 2020.
Renaissance Technologies (RenTech)'s largest addition to DiaMedica Therapeutics Inc. (DMAC) was in Q2 2020, adding 104,700 shares worth $726,000.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 52,523 shares of DiaMedica Therapeutics Inc. (DMAC), valued at approximately $355,581.
As of the Q1 2026 filing, DiaMedica Therapeutics Inc. (DMAC) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in DiaMedica Therapeutics Inc. (DMAC) was 153,100 shares, as reported at the end of Q1 2021.